[Clinical aspects of prenatal prevention of rhesus incompatibility].
The postnatal treatment with anti-D immunoglobulin to prevent rhesus sensitization is successful in about 90% of all rhesus-negative mothers at risk. Failures derive mostly from large fetomaternal hemorrhages during the last months of pregnancy. Studies from Canada, Great Britain and Sweden have shown that the injection of an additional dosage of anti-D during the 28th to 34th week of pregnancy results in a further 90% reduction of the failure rate. Although there is only a limited number of cases of hemolytic diseases in the newborn, the cost-effect ratio of this prophylactic treatment calculated for the Federal Republic of Germany shows not only a medical but also an economic benefit.
Maas
D H
DH
Gynäkologisch-geburtshilfliche Abteilung des Kreiskrankenhauses Schwäbisch Gmünd, Mutlangen, BRD.
D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage*; D003362:Cost-Benefit Analysis; D004899:Erythroblastosis, Fetal / Q000097:blood / Q000191:economics / Q000517:prevention & control; D005260:Female; D005865:Gestational Age; D006801:Humans; D007072:Immunoglobulin D / Q000276:immunology*; D007231:Infant, Newborn; D011247:Pregnancy; D011295:Prenatal Care / Q000191:economics; D012203:Rh Isoimmunization / Q000097:blood / Q000191:economics / Q000517:prevention & control*; D012204:Rh-Hr Blood-Group System / Q000097:blood*
D000888:Antibodies, Anti-Idiotypic; D007072:Immunoglobulin D; D012204:Rh-Hr Blood-Group System; C026410:Rho(D) antigen
Klinische Aspekte der antenatalen Rhesus-Prophylaxe.